Moura M - Search Results

1

Protein Phosphatase 1 inactivates Mps1 to ensure efficient Spindle Assembly Checkpoint silencing.

Moura M, Osswald M, Leça N, Barbosa J, Pereira AJ, Maiato H, Sunkel CE, Conde C. Moura M, et al. Elife. 2017 May 2;6:e25366. doi: 10.7554/eLife.25366. Elife. 2017. PMID: 28463114 Free PMC article.

2

Phosphatases in Mitosis: Roles and Regulation.

Moura M, Conde C. Moura M, et al. Biomolecules. 2019 Feb 7;9(2):55. doi: 10.3390/biom9020055. Biomolecules. 2019. PMID: 30736436 Free PMC article. Review.

3

Identification of SPRY4 as a Novel Candidate Susceptibility Gene for Familial Nonmedullary Thyroid Cancer.

Marques IJ, Gomes I, Pojo M, Pires C, Moura MM, Cabrera R, Santos C, van IJcken WFJ, Teixeira MR, Ramalho JS, Leite V, Cavaco BM. Marques IJ, et al. Among authors: moura mm. Thyroid. 2021 Sep;31(9):1366-1375. doi: 10.1089/thy.2020.0290. Epub 2021 Jun 3. Thyroid. 2021. PMID: 33906393

4

Cell cycle deregulation and TP53 and RAS mutations are major events in poorly differentiated and undifferentiated thyroid carcinomas.

Pita JM, Figueiredo IF, Moura MM, Leite V, Cavaco BM. Pita JM, et al. J Clin Endocrinol Metab. 2014 Mar;99(3):E497-507. doi: 10.1210/jc.2013-1512. Epub 2014 Jan 13. J Clin Endocrinol Metab. 2014. PMID: 24423316

5

Identification of somatic TERT promoter mutations in familial nonmedullary thyroid carcinomas.

Marques IJ, Moura MM, Cabrera R, Pinto AE, Simões-Pereira J, Santos C, Menezes FD, Montezuma D, Henrique R, Rodrigues Teixeira M, Leite V, Cavaco BM. Marques IJ, et al. Among authors: moura mm. Clin Endocrinol (Oxf). 2017 Oct;87(4):394-399. doi: 10.1111/cen.13375. Epub 2017 Jun 19. Clin Endocrinol (Oxf). 2017. PMID: 28502101

6

Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas.

Moura MM, Cavaco BM, Pinto AE, Domingues R, Santos JR, Cid MO, Bugalho MJ, Leite V. Moura MM, et al. Br J Cancer. 2009 Jun 2;100(11):1777-83. doi: 10.1038/sj.bjc.6605056. Epub 2009 Apr 28. Br J Cancer. 2009. PMID: 19401695 Free PMC article.

7

High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.

Moura MM, Cavaco BM, Pinto AE, Leite V. Moura MM, et al. J Clin Endocrinol Metab. 2011 May;96(5):E863-8. doi: 10.1210/jc.2010-1921. Epub 2011 Feb 16. J Clin Endocrinol Metab. 2011. PMID: 21325462

8

TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.

Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, Celestino R, Almeida A, Salgado C, Eloy C, Castro P, Prazeres H, Lima J, Amaro T, Lobo C, Martins MJ, Moura M, Cavaco B, Leite V, Cameselle-Teijeiro JM, Carrilho F, Carvalheiro M, Máximo V, Sobrinho-Simões M, Soares P. Melo M, et al. Among authors: moura m. J Clin Endocrinol Metab. 2014 May;99(5):E754-65. doi: 10.1210/jc.2013-3734. Epub 2014 Jan 29. J Clin Endocrinol Metab. 2014. PMID: 24476079 Free PMC article.

9

Identification and characterization of two novel germline RET variants associated with medullary thyroid carcinoma.

Silva AL, Carmo F, Moura MM, Domingues R, Espadinha C, Leite V, Cavaco B, Bugalho MJ. Silva AL, et al. Among authors: moura mm. Endocrine. 2015 Jun;49(2):366-72. doi: 10.1007/s12020-015-0559-0. Epub 2015 Mar 1. Endocrine. 2015. PMID: 25725622

10

RAS proto-oncogene in medullary thyroid carcinoma.

Moura MM, Cavaco BM, Leite V. Moura MM, et al. Endocr Relat Cancer. 2015 Oct;22(5):R235-52. doi: 10.1530/ERC-15-0070. Endocr Relat Cancer. 2015. PMID: 26285815 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

958 results

Search Page